Literature DB >> 32554527

Piperacillin/tazobactam-induced coagulopathy in a patient through a vitamin K-dependent mechanism.

Zhenwei Yu1, Huadong Chen2.   

Abstract

Haematologic side effects associated with piperacillin/tazobactam (PTZ) treatment are rare but can be fatal. The exact mechanism by which PTZ causes haemorrhages has not been determined. We report the case of a patient who received PTZ treatment and developed a coagulopathy through a vitamin K-dependent mechanism. A 70-year-old female patient was admitted to the intensive care unit because she had a severe case of pneumonia and a pulmonary thromboembolism. Empirical antibiotic treatment using PTZ was started. Her international normalised ratio (INR) was already increased and became elevated again when PTZ was restarted. Her coagulopathy was reversed by supplementation with vitamin K. We conclude that PTZ can induce coagulopathy through a vitamin K-dependent mechanism and, to our knowledge, this is the first case report to suggest that mechanism. We suggest that patients at risk for a vitamin K deficiency should be monitored for coagulopathy when piperacillin or any other board spectrum antibiotic is administered. © European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  adverse effects; anticoagulation; bleeding disorders & coagulopathies; clinical pharmacy; infectious diseases

Mesh:

Substances:

Year:  2020        PMID: 32554527      PMCID: PMC8239263          DOI: 10.1136/ejhpharm-2019-002182

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  7 in total

1.  A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins.

Authors:  Qing Xi Ooi; Daniel F B Wright; R Campbell Tait; Geoffrey K Isbister; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 2.  Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature.

Authors:  Musa Alzahrani; Ibrahim Alrumaih; Fahad Alhamad; Ahmed Abdel Warith
Journal:  Platelets       Date:  2018-06-04       Impact factor: 3.862

Review 3.  Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

4.  Fecal concentrations of bacterially derived vitamin K forms are associated with gut microbiota composition but not plasma or fecal cytokine concentrations in healthy adults.

Authors:  J Philip Karl; Mohsen Meydani; Junaidah B Barnett; Sally M Vanegas; Kathryn Barger; Xueyan Fu; Barry Goldin; Anne Kane; Helen Rasmussen; Pajau Vangay; Dan Knights; Satya S Jonnalagadda; Edward Saltzman; Susan B Roberts; Simin N Meydani; Sarah L Booth
Journal:  Am J Clin Nutr       Date:  2017-08-16       Impact factor: 7.045

5.  Role of prophylactic vitamin K in preventing antibiotic induced hypoprothrombinemia.

Authors:  Farookh Aziz; Prashant Patil
Journal:  Indian J Pediatr       Date:  2014-10-10       Impact factor: 1.967

6.  Platelet Dysfunction and Intracerebral Hemorrhage in a Patient Treated with Empiric Piperacillin-Tazobactam in the Neurocritical Care Unit.

Authors:  Matthew Bower; Candace Borders; Andrew Schnure; Leonid Groysman; Minh-Ha Tran
Journal:  World Neurosurg       Date:  2018-03-16       Impact factor: 2.104

7.  Coagulopathy with piperacillin administration in cystic fibrosis: two case reports.

Authors:  P J Rye; G Roberts; R E Staugas; A J Martin
Journal:  J Paediatr Child Health       Date:  1994-06       Impact factor: 1.954

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.